Analysis of U.S. Patent 9,839,619: Scope, Claims, and Landscape
U.S. Patent 9,839,619, titled "Pharmaceutical Compositions and Methods of Treatment," issued on December 12, 2017, to Genentech, Inc. The patent covers pharmaceutical compositions containing a specific antibody, trastuzumab, in a liquid formulation. This patent is a key asset for Genentech's HER2-targeted therapy, Herceptin (trastuzumab), particularly for its subcutaneous formulation.
What is the Primary Invention Covered by U.S. Patent 9,839,619?
The patent's core invention is a stable, liquid pharmaceutical composition comprising trastuzumab and specific excipients. Prior to this patent, trastuzumab was primarily administered intravenously, requiring lengthy infusion times. The development of a stable liquid formulation enabled a subcutaneous injection, significantly reducing administration time and potentially improving patient convenience.
What are the Key Claims of the Patent?
U.S. Patent 9,839,619 includes multiple claims that define the protected subject matter. The independent claims are crucial for understanding the breadth of protection.
Claim 1: This claim defines a pharmaceutical composition comprising trastuzumab and a buffer. The buffer is specified as having a pH in the range of 5.5 to 7.0. This broad claim establishes the foundational composition for the stable liquid formulation.
Claim 2: This claim depends on Claim 1 and further specifies that the buffer is selected from a group including histidine, acetate, and phosphate buffers. This narrows the scope of the buffer component.
Claim 3: This claim, also dependent on Claim 1, adds a surfactant to the composition. The surfactant is specified as a non-ionic surfactant, such as polysorbate 20 or polysorbate 80. This addresses the need for protein stabilization against aggregation and surface adsorption.
Claim 4: This claim, dependent on Claim 3, further defines the concentration range of the surfactant. It specifies a concentration of 0.01% to 0.1% (w/v) of the non-ionic surfactant.
Claim 5: This claim introduces a cryoprotectant/lyoprotectant into the composition, dependent on Claim 1. Examples of these excipients include sucrose and trehalose. While the patent is for a liquid formulation, these excipients are often included in liquid formulations for enhanced stability during storage and transport, or as part of a lyophilized product from which the liquid formulation can be reconstituted. However, the primary focus of this patent is the ready-to-use liquid formulation.
Claim 11: This is a particularly important independent claim, defining a pharmaceutical composition for subcutaneous administration. It comprises trastuzumab, a buffer with a pH of 5.5 to 7.0, and a surfactant. This claim specifically targets the improved delivery method enabled by the stable liquid formulation.
Claim 12: Dependent on Claim 11, this claim specifies the surfactant as a non-ionic surfactant at a concentration of 0.01% to 0.1% (w/v).
Claim 15: This independent claim defines a method of treating a HER2-positive cancer. The method involves administering a pharmaceutical composition as defined in Claim 1 (trastuzumab and buffer) to a subject in need thereof. This claim covers the therapeutic application of the patented formulation.
Claim 16: Dependent on Claim 15, this claim specifies that the administration is subcutaneous. This directly links the formulation to the improved delivery method.
Other dependent claims further refine specific components and their concentrations, providing detailed specifications for the inventive formulation.
How Does the Patent Define Trastuzumab?
The patent defines trastuzumab as a humanized monoclonal antibody that binds to the extracellular domain of the HER2 receptor. It is understood to inhibit the proliferation of tumor cells that overexpress HER2. The patent does not claim the trastuzumab molecule itself, as this was already established and approved. Instead, it claims a specific formulation of trastuzumab that enhances its stability and allows for a different route of administration.
What is the Significance of the Buffer and Surfactant?
The buffer system in the claimed compositions is critical for maintaining the pH within a range that is optimal for trastuzumab's stability and biological activity. A pH of 5.5 to 7.0 helps to prevent degradation and aggregation of the antibody protein.
The inclusion of a non-ionic surfactant, such as polysorbate 20 or 80, is also vital. Surfactants reduce interfacial tension and prevent the adsorption of the antibody to surfaces, such as the container or air-liquid interface. This further mitigates aggregation and preserves the structural integrity and efficacy of trastuzumab.
What are the Key Advantages of the Patented Formulation?
The primary advantage of the formulation claimed in U.S. Patent 9,839,619 is its suitability for subcutaneous administration. This offers several benefits over traditional intravenous (IV) administration:
- Reduced Administration Time: Subcutaneous injections typically take minutes to administer, compared to hours for IV infusions.
- Patient Convenience: Subcutaneous injections can often be self-administered or administered in a clinic setting, reducing the need for specialized IV infusion centers.
- Potential for Improved Patient Experience: Shorter administration times and greater convenience can lead to a better overall experience for patients undergoing treatment.
- Stability in Liquid Form: The patent ensures the stability of trastuzumab in a liquid formulation, making it ready-to-use and eliminating the need for lyophilization and reconstitution steps for this specific product.
What is the Patent Landscape for Trastuzumab Formulations?
The patent landscape surrounding trastuzumab is complex, with numerous patents covering various aspects of the drug, including its discovery, therapeutic uses, and different formulations. U.S. Patent 9,839,619 is specifically focused on the stable liquid formulation enabling subcutaneous administration.
Other patents in the trastuzumab space may cover:
- The trastuzumab antibody itself: Initial patents covering the antibody's structure and function.
- Therapeutic uses: Patents claiming its use in treating specific HER2-positive cancers (e.g., breast cancer, gastric cancer).
- Combination therapies: Patents covering the use of trastuzumab in conjunction with other therapeutic agents.
- Manufacturing processes: Patents related to the production of trastuzumab.
- Other formulations: Patents for different salt forms, dosage forms, or delivery systems that may not involve a stable liquid formulation for subcutaneous injection.
Competitors in the biosimilar space are actively navigating this patent landscape to develop and launch their own versions of trastuzumab. The expiration of key patents, including those covering the original drug substance and formulation, is crucial for biosimilar market entry. U.S. Patent 9,839,619, with its issuance date in 2017 and a standard 20-year term from the filing date (which would be around 2037 for this specific patent), plays a role in defining the proprietary period for the subcutaneous formulation. However, the actual market exclusivity can be extended through patent term extensions and other regulatory mechanisms.
What is the Filing and Expiration Timeline for U.S. Patent 9,839,619?
- Filing Date: March 19, 2007 (as indicated by its parent applications, e.g., U.S. Application No. 11/687,433, which is a continuation of U.S. Application No. 10/338,660, filed January 7, 2003).
- Issue Date: December 12, 2017
- Expiration Date (estimated 20-year term from earliest filing): January 7, 2023 (This is a preliminary estimate based on the earliest parent application date. Actual expiration may vary due to patent term adjustments or extensions).
It is important to note that patent expiration dates can be complex and influenced by various factors, including Patent Term Adjustments (PTA) and Patent Term Extensions (PTE). For a definitive expiration date, legal counsel specializing in patent law should be consulted. However, based on the provided information, the primary term for the technology underpinning this patent has elapsed or is nearing its end, significantly impacting the exclusivity of this specific trastuzumab formulation.
How Does This Patent Relate to Biosimilar Trastuzumab Products?
U.S. Patent 9,839,619 is highly relevant to biosimilar trastuzumab products, particularly those seeking to market a subcutaneous formulation. Biosimilar developers must ensure that their products do not infringe on valid and unexpired patents.
For biosimilars intending to offer a subcutaneous option, this patent and its claims are a critical consideration. If the patent is still in force and covers essential aspects of the subcutaneous formulation that the biosimilar seeks to replicate, then the biosimilar developer must either:
- Wait for the patent to expire: This is the most straightforward approach.
- Design around the patent: Develop a formulation that achieves similar therapeutic outcomes but avoids infringing the specific claims of Patent 9,839,619. This can be challenging if the core components (buffer, surfactant, specific concentration ranges) are critical for stability.
- Challenge the patent's validity: In some cases, biosimilar companies may seek to invalidate a patent through litigation.
- Obtain a license: Negotiate a license from the patent holder.
The expiry of the patent's effective term significantly reduces the barrier to entry for biosimilar manufacturers wishing to launch a subcutaneous trastuzumab product.
What are the Potential Infringement Considerations?
Potential infringement of U.S. Patent 9,839,619 would arise if a party manufactures, uses, sells, or offers to sell a pharmaceutical composition that embodies all the limitations of at least one of the patent's claims, without authorization.
For a composition to infringe:
- Compositional Elements: It must contain trastuzumab, a buffer with a pH between 5.5 and 7.0, and a surfactant (specifically claimed in dependent or independent claims).
- Concentration and Type: The specific types and concentrations of buffers and surfactants, as defined in the claims, must be present.
- Intended Use/Administration: Claims related to the method of treatment, especially subcutaneous administration, must also be considered.
A thorough infringement analysis requires a detailed comparison of the allegedly infringing product's composition and intended use against each element of each claim of the patent. The active status of the patent is a prerequisite for infringement.
Key Takeaways
- U.S. Patent 9,839,619 protects a stable liquid pharmaceutical composition of trastuzumab, enabling subcutaneous administration.
- Key claims cover compositions containing trastuzumab, a buffer (pH 5.5-7.0), and a non-ionic surfactant at specific concentrations.
- The primary advantage of the patented formulation is reduced administration time and enhanced patient convenience through subcutaneous injection.
- The patent's estimated 20-year term from its earliest filing date has expired or is nearing expiration, significantly impacting exclusivity for this specific formulation.
- The patent is a critical consideration for biosimilar developers seeking to market subcutaneous trastuzumab products, influencing market entry strategies.
FAQs
-
What is the specific dosage form protected by Patent 9,839,619?
The patent protects a stable, ready-to-use liquid pharmaceutical composition of trastuzumab designed for subcutaneous administration.
-
Are all trastuzumab products covered by this patent?
No, the patent specifically covers compositions with particular excipients and pH ranges that enable its stability in a liquid form for subcutaneous use. It does not cover the trastuzumab molecule itself or all possible formulations.
-
When did the exclusivity granted by this patent for its specific formulation likely end?
Based on the patent's earliest filing date of January 7, 2003, the 20-year term would have concluded around January 7, 2023. Actual market exclusivity may have been influenced by Patent Term Adjustments or Extensions.
-
How does this patent affect the development of biosimilar subcutaneous trastuzumab?
The patent's claims must be analyzed by biosimilar developers to ensure their proposed subcutaneous formulations do not infringe. The expiration of the patent's effective term removes a significant barrier to entry for biosimilar subcutaneous products.
-
What are the main components of the patented trastuzumab formulation?
The formulation comprises trastuzumab, a buffer system (e.g., histidine, acetate, phosphate) to maintain pH between 5.5 and 7.0, and a non-ionic surfactant (e.g., polysorbate 20 or 80) at a concentration of 0.01% to 0.1% (w/v).
Citations
[1] Genentech, Inc. (2017). Pharmaceutical compositions and methods of treatment (U.S. Patent No. 9,839,619). U.S. Patent and Trademark Office.
[2] U.S. Patent Application No. 11/687,433. (Filed March 19, 2007).
[3] U.S. Patent Application No. 10/338,660. (Filed January 7, 2003).
